Abstract: In some examples, a CSS-MBs includes a solid magnetic core, a first shell material which surrounds the solid magnetic core and a second shell material which surrounds the first shell material. The first shell material may be a protective layer. The first shell material may include an inert carbon material. The second shell material may be have surface chemistry which allows for selective interaction of the CSS-MB with certain biomolecules under various buffer conditions.

Abstract: Embodiments of the disclosure are drawn to apparatuses, systems, and methods for enrichment and separation of nucleic acids by size. A sample may include a mixture of nucleic acids of various sizes, and the nucleic acids of interest may be below a particular size threshold. An example enrichment method may include mixing the sample with a first substrate (e.g., magnetic beads). The method may include separating nucleic acids above a first size threshold form a remainder of the sample using the first substrate. The method may include mixing the nucleic acids in the remainder of the sample (e.g., nucleic acids below’ the size threshold) with a second substrate and recovering the nucleic acids below the first size threshold from the second substrate.

Abstract: Cancer is a genetic disease initiated by somatic mutations and progressed by an accumulation of genomic aberrations. Differentiating cancer driver somatic mutations from passenger and benign mutations is a critical step toward better understanding of cancer biology. It also provides important insights into cancer detection and prognosis monitoring. Provided herein are machine learning methods that utilize a deep-learning framework to predict mutation-associated pathogenicity, including cancer-related pathogenicity risk of somatic mutations. The methods incorporate not only an annotation comprising functional features, genomic features, epigenetic features, and other annotated features related to the mutation, but also a separate annotation including the surrounding sequence content of the test mutation. The methods can provide a quantitative score from the two or more annotation sets of a mutant reflecting the pathogenic risk of a mutation, including those involved in carcinogenesis and cancer progression.

Abstract: Disclosed herein are magnetic nanoparticles, compositions and kits comprising the magnetic nanoparticles, methods of making the magnetic nanoparticles, and methods of using the magnetic nanoparticles to enrich biological targets.

Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.

Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.

Abstract: The present invention provides genetic markers and biomarkers that are associated with anemia induced by ribavirin therapy. The genetic markers are located in the ITPA gene and elsewhere on human chromosome 20 and the biomarkers are low ITPA activity phenotypes. These markers of ribavirin-induced anemia are useful, inter alia, to identify patients who are least likely to develop anemia upon treatment with ribavirin pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with ribavirin, and in methods for selecting the most appropriate therapy for such patients.